US 11,898,180 B2
Compositions and methods for amino acid depletion therapy
Johnson Yiu-Nam Lau, Houston, TX (US); Yun Chung Leung, Shatin (HK); Kuo-Ming Yu, Taipei (TW); Yuk-Keung Yeung, Kwai Chung (HK); Pui Shi Pang, Kowloon (HK); and Qui-Lim Choo, El Cerrito, CA (US)
Assigned to Avalon Polytom (HK) Limited, Central (HK)
Appl. No. 16/639,078
Filed by AVALON POLYTOM (HK) LIMITED, Central (HK)
PCT Filed Aug. 16, 2018, PCT No. PCT/US2018/000208
§ 371(c)(1), (2) Date Feb. 13, 2020,
PCT Pub. No. WO2019/035935, PCT Pub. Date Feb. 21, 2019.
Claims priority of provisional application 62/546,489, filed on Aug. 16, 2017.
Claims priority of provisional application 62/591,102, filed on Nov. 27, 2017.
Prior Publication US 2021/0189370 A1, Jun. 24, 2021
Int. Cl. C12N 9/78 (2006.01); C07K 1/18 (2006.01)
CPC C12N 9/78 (2013.01) [C07K 1/18 (2013.01); C12Y 305/03001 (2013.01)] 4 Claims
 
1. A method of selectively inhibiting a cancer cell having low asparaginase expression, comprising:
introducing an arginase to a media in contact with the cancer cell to reduce arginine concentration in the media to a concentration effective to inhibit growth of the cancer cell; and
introducing an asparaginase to the media to reduce asparagine concentration in the media to a concentration effective to inhibit growth of the cancer cell,
wherein the arginase and the asparaginase in combination provide a synergistic effect in reducing viability of the cancer cell, wherein the synergistic effect exceeds additive effects of monotherapies with the arginase and the asparaginase in inhibition of growth of the cancer cell having low asparaginase expression.